191 related articles for article (PubMed ID: 9849695)
1. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ
Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
[TBL] [Abstract][Full Text] [Related]
2. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation.
Lynch BA; Vasef MA; Comito M; Gilman AL; Lee N; Ritchie J; Rumelhart S; Holida M; Goldman F
Bone Marrow Transplant; 2003 Sep; 32(5):527-33. PubMed ID: 12942101
[TBL] [Abstract][Full Text] [Related]
3. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
4. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.
Juvonen E; Aalto SM; Tarkkanen J; Volin L; Mattila PS; Knuutila S; Ruutu T; Hedman K
Bone Marrow Transplant; 2003 Jul; 32(1):97-102. PubMed ID: 12815484
[TBL] [Abstract][Full Text] [Related]
5. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
6. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
Chiang KY; Hazlett LJ; Godder KT; Abhyankar SH; Christiansen NP; van Rhee F; Lee CG; Bridges K; Parrish RS; Henslee-Downey PJ
Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352
[TBL] [Abstract][Full Text] [Related]
8. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
[TBL] [Abstract][Full Text] [Related]
9. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC
Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
[TBL] [Abstract][Full Text] [Related]
10. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia.
Buyck HC; Ball S; Junagade P; Marsh J; Chakrabarti S
Bone Marrow Transplant; 2009 May; 43(10):813-6. PubMed ID: 19104495
[TBL] [Abstract][Full Text] [Related]
11. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
Xu LP; Huang XJ; Liu DH; Chen YH; Shi HX; Chen DB
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
13. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
14. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
16. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
[TBL] [Abstract][Full Text] [Related]
17. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
18. T cell lymphoproliferative disorder following bone marrow transplantation for severe aplastic anemia.
Wang LC; Lu MY; Yu J; Jou ST; Chiang IP; Lin KH; Lin DT
Bone Marrow Transplant; 2000 Oct; 26(8):893-7. PubMed ID: 11081391
[TBL] [Abstract][Full Text] [Related]
19. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders.
Abed N; Casper JT; Camitta BM; Margolis D; Trost B; Orentas R; Chang CC
Bone Marrow Transplant; 2004 Feb; 33(3):321-7. PubMed ID: 14688820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
